Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Cellular Biomedicine Starts China Trial of Liver Cancer Treatment

publication date: Mar 25, 2013
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Cellular Biomedicine Group has started a clinical trial in China of an innovative personalized treatment for liver cancer. Through a collaboration with Shanghai's PLA 85 Hospital, the company will test its TC-DC (Tumor Stem Cell Specific Dendritic Cell) therapy in patients with hepatocellular carcinoma (HCC). CBMG has facilities in Shanghai and WuXi, though its headquarters are in Palo Alto, California. More details....

Stock Symbol: (OTCQB: CBMG)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...